Treatment(s) already received-Surgical excision Posts on Medivizor
Navigation Menu

Treatment(s) already received-Surgical excision Posts on Medivizor

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Posted by on Sep 30, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) given after surgery in patients with stage II melanoma. The data showed that pembrolizumab given after surgery for up to 1 year significantly reduced the risk of cancer recurrence or death in these patients. Some background Melanoma is one of the most...

Read More

Long-term outcomes of pembrolizumab therapy for patients with stage III melanoma removed surgically

Long-term outcomes of pembrolizumab therapy for patients with stage III melanoma removed surgically

Posted by on May 16, 2021 in Melanoma | 0 comments

In a nutshell The aim of this study was to investigate the long-term safety and effectiveness of pembrolizumab (Keytruda) for patients with stage III melanoma that was surgically removed. The study found that patients treated with pembrolizumab were more likely to have an improved outcome.   Some background Melanoma is one of the most...

Read More

Evaluating treatment options after surgery for patients with high-risk melanoma.

Evaluating treatment options after surgery for patients with high-risk melanoma.

Posted by on Apr 11, 2021 in Melanoma | 0 comments

In a nutshell The aim of this study was to evaluate different types of therapy after surgery for patients with high-risk melanoma. The study found that add-on targeted therapy or immunotherapy was likely to decrease the risk of disease progression in these patients. Some background Melanoma is a form of skin cancer. Treatment for early-stage...

Read More

Using long-term CT and PET/CT scans to identify metastatic recurrence in patients with resected melanoma.

Using long-term CT and PET/CT scans to identify metastatic recurrence in patients with resected melanoma.

Posted by on Feb 26, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated how effective regular scanning is in identifying metastatic recurrence in patients with stage III melanoma that was surgically removed. Results showed that scanning every 6 or 12 months was reasonably good at detecting metastatic recurrence. Some background Melanoma is a form of aggressive skin cancer. Treatment...

Read More

Can biological therapies nivolumab and ipilimumab prevent stage IV melanoma from returning?

Can biological therapies nivolumab and ipilimumab prevent stage IV melanoma from returning?

Posted by on Jun 6, 2020 in Melanoma | 0 comments

In a nutshell This study examined if biological therapies nivolumab (Opdivo) and ipilimumab (Yervoy) could safely prevent cancer return in patients with stage IV melanoma that has been surgically removed. The results showed that nivolumab and ipilimumab were effective at preventing recurrence but nivolumab alone was safer for patients. Some...

Read More

Restaging warranted prior to adjuvant therapy in patients with resected stage IIIB and IIIC melanoma.

Restaging warranted prior to adjuvant therapy in patients with resected stage IIIB and IIIC melanoma.

Posted by on May 31, 2019 in Melanoma | 0 comments

In a nutshell This article investigated the need for restaging in patients with stage IIIB and IIIC melanoma before starting adjuvant therapy (AT; treatment after surgery).   The authors concluded that restaging should be considered for these high-risk patients before starting the AT.  Some background Melanoma a type of skin cancer...

Read More

PET is effective detecting recurrences in stage 3 melanoma

PET is effective detecting recurrences in stage 3 melanoma

Posted by on Jun 4, 2018 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness of the imaging method PET (detects active cancer lesions) in detecting relapses after surgery in stage 3 melanoma patients. Researchers suggested that PET allows the detection of most recurrences. Some background Stage 3 melanoma is associated with a high rate of recurrences. Follow-up of...

Read More

Looking for participants to test the safety and effectiveness of a vaccine combined with TLR agonists to treat melanoma

Looking for participants to test the safety and effectiveness of a vaccine combined with TLR agonists to treat melanoma

Posted by on Feb 19, 2017 in Melanoma | 0 comments

In a nutshell This phase 1/2 trial aims to test the safety and effectiveness of a combined treatment with the new vaccine LPV7 and TLR agonists in advanced melanoma patients after surgery. The main outcome to be measured will be the treatment toxicity and response of the tumors to the treatment. This trial is recruiting in Houston, Texas and...

Read More